513 assets in Ovarian Cancer

Therapeutic assets addressing Ovarian Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tilt-123 Ovarian Cancer	TILT Biotherapeutics Ltd.	P1/2	CC (45)
Transcon Il-2 Β/Γ Ovarian Cancer	Ascendis Pharma Oncology Division A/S	P1/2	CC (45)
Transcon Tlr7/8 Agonist Ovarian Cancer	Ascendis Pharma Oncology Division A/S	P1/2	CC (45)
Vio-01 Ovarian Cancer	Valerio Therapeutics	P1/2	CC (45)
Withaferin A Ovarian Cancer	Sham Sunder Kakar	P1/2	CC (45)
Mirvetuximab Ovarian Cancer	Shattuck Labs, Inc.	P1	CC (44)
Nirogacestat Ovarian Cancer	SpringWorks Therapeutics, Inc.	P2	CC (44)
Bms-986500 Ovarian Cancer	Bristol-Myers Squibb	P1	CC (43)
Cabozantinib Ovarian Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Copanlisib Ovarian Cancer	M.D. Anderson Cancer Center	P2	CC (43)
Denosumab Ovarian Cancer	National University Hospital, Singapore	P1	CC (43)
Elimusertib Ovarian Cancer	National Cancer Institute (NCI)	P1	CC (43)
Erx-315 Ovarian Cancer	EtiraRx Australia Pty Ltd	P1	CC (43)
Etc-159 Ovarian Cancer	National University Hospital, Singapore	P1	CC (43)
Etigilimab Ovarian Cancer	M.D. Anderson Cancer Center	P2	CC (43)
Gartisertib Ovarian Cancer	University of Alabama at Birmingham	P1	CC (43)
Hwk-016, Mucin-16-Targeted Adc Ovarian Cancer	Whitehawk Therapeutics, Inc.	P1	CC (43)
Ipn 60090 Ovarian Cancer	M.D. Anderson Cancer Center	P1	CC (43)
mov18 ige Ovarian Cancer	Epsilogen Ltd	P1	CC (43)
Nogapendekin Alfa Inbakicept Ovarian Cancer	ImmunityBio, Inc.	P2	CC (43)
Opb-101 Ovarian Cancer	Outpace Bio, Inc.	P1	CC (43)
Prgn-3005 Ultracar-T Cells Ovarian Cancer	Precigen, Inc	P1	CC (43)
Promitil Ovarian Cancer	Lipomedix Pharmaceuticals Inc.	P2	CC (43)
Re-Stimulated Tumor-Infiltrating Lymphocytes Ovarian Cancer	University Health Network, Toronto	P1	CC (43)
Sotigalimab Ovarian Cancer	Nordic Society of Gynaecological Oncology - Clinical Trials Unit	P2	CC (43)
Ucmym802 Ovarian Cancer	UTC Therapeutics Inc.	P1	CC (43)
e-602 Ovarian Cancer	Palleon Pharmaceuticals, Inc.	P1/2	CC (42)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-5901 (99.0%) -(Ighd) -Ighj302 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-1101 (96.8%) -Igkj401 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa Ovarian Cancer	Kineta Inc.	P1/2	CC (42)
il15-transpresenting wt1-targeted dendritic cell vaccine Ovarian Cancer	University Hospital, Antwerp	P1/2	CC (42)
sl-172154 Ovarian Cancer	Shattuck Labs, Inc.	P1	CC (42)
Ctim-76 Ovarian Cancer	Context Therapeutics Inc.	P1	CC (41)
Cytokine-Induced Memory-Like Natural Killer Cells Ovarian Cancer	Dana-Farber Cancer Institute	P1	CC (41)
Drug Product De-Til-0255 Ovarian Cancer	Nurix Therapeutics, Inc.	P1	CC (41)
gb-5267 - iv only Ovarian Cancer	Roswell Park Cancer Institute	P1	CC (41)
hs-20093 Ovarian Cancer	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1	CC (41)
Lunresertib Ovarian Cancer	University Health Network, Toronto	P1	CC (41)
lyl797 Ovarian Cancer	Lyell Immunopharma, Inc.	P1	CC (41)
men2501 Ovarian Cancer	Stemline Therapeutics, Inc.	P1	CC (41)
MGC026 Ovarian Cancer	MacroGenics	P1	CC (41)
Tulmimetostat Ovarian Cancer	Lan Coffman	P1	CC (41)
[111in]-fpi-1967 Ovarian Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (40)
177lu-betabart Ovarian Cancer	Radiopharm Theranostics, Ltd	P1/2	CC (40)
[203pb]pb-psv359 Ovarian Cancer	Perspective Therapeutics	P1/2	CC (40)
[212pb]pb-psv359 Ovarian Cancer	Perspective Therapeutics	P1/2	CC (40)
[225Ac]-FPI-1966 Ovarian Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (40)
a2b543 Ovarian Cancer	A2 Biotherapeutics Inc.	P1/2	CC (40)
a2b694 Ovarian Cancer	A2 Biotherapeutics Inc.	P1/2	CC (40)
Ace-86225106 Ovarian Cancer	Acerand Therapeutics (Shanghai) Limited	P1/2	CC (40)
Acetylcysteine Ovarian Cancer	University of California, Irvine	P1/2	CC (40)
Alnodesertib Ovarian Cancer	Artios Pharma Ltd	P1/2	CC (40)

Showing 251 to 300 of 513 assets

PreviousPage 6 of 11Next